LeonaBio, Inc.

LONA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$7.51

−$0.145 · -1.89%

Aug 24, 10:25 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

46/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Fair Value

Momentum

Gaining

Sentiment

Bullish

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Mark J. Litton
Listed since: Sep 18, 2020
Employees: 19